42,199 Shares in Cellebrite DI Ltd. $CLBT Bought by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 42,199 shares of the company’s stock, valued at approximately $675,000.

A number of other hedge funds have also recently modified their holdings of CLBT. Voss Capital LP increased its stake in shares of Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after acquiring an additional 1,306,398 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after purchasing an additional 570,000 shares during the period. Invesco Ltd. grew its holdings in Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after purchasing an additional 209,473 shares during the period. Pertento Partners LLP increased its stake in shares of Cellebrite DI by 11.8% during the second quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after purchasing an additional 309,988 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Cellebrite DI by 61.3% during the second quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock valued at $39,200,000 after purchasing an additional 931,300 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

CLBT has been the topic of several recent research reports. Lake Street Capital upped their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Bank of America increased their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC lifted their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $18.88 on Wednesday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company has a market cap of $4.52 billion, a P/E ratio of 60.90, a PEG ratio of 3.29 and a beta of 1.29. The stock’s fifty day moving average price is $17.71 and its 200-day moving average price is $16.68.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The business had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.Cellebrite DI’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period last year, the firm posted $0.14 EPS. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.